Prometheus Biosciences, Inc. (RXDX)
| Market Cap | n/a |
| Revenue (ttm) | 1,229 |
| Net Income (ttm) | -37,138 |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public of...
Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.
About RXDX
Prometheus Biosciences is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, we are developing ... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Pending |
| CEO Mark C. McKenna | Employees 24 |
| Stock Exchange NASDAQ | Ticker Symbol RXDX |
Financial Performance
In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.